Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPD | P32754 | 11/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11445400 | 0.80 | ALDH1A1 (0.78) | ALDH1A1L3MBTL1LMNAHSD17B10GLA | |
| SCHEMBL29110416 | 0.80 | POLB (0.58) | HPDHSD17B10POLB | |
| SCHEMBL30089886 | 0.77 | HSD17B10 (0.72) | ALDH1A1LMNAHPDHSD17B10POLB | |
| SCHEMBL30089888 | 0.77 | HSD17B10 (0.72) | ALDH1A1LMNAHPDHSD17B10POLB | |
| SCHEMBL29110410 | 0.77 | HSD17B10 (0.72) | ALDH1A1LMNAHPDHSD17B10POLB | |
| SCHEMBL9954234 | 0.73 | ALDH1A1 (0.53) | ALDH1A1HPDPOLB | |
| SCHEMBL9954358 | 0.73 | ALDH1A1 (0.53) | ALDH1A1HPDPOLB | |
| SCHEMBL9953564 | 0.72 | TDO2 (0.48) | ALDH1A1L3MBTL1HPDGLAPOLB | |
| SCHEMBL9952718 | 0.72 | TDO2 (0.48) | ALDH1A1L3MBTL1HPDGLAPOLB | |
| SCHEMBL5864107 | 0.71 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1LMNAHPDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095214-A1 | QUINAZOLINONE LINKED PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095214-A1 | QUINAZOLINONE LINKED PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | GABRA1, CYP2C19, GABRA5 | ALDH1A1 227/4885L3MBTL1 4647/4885LMNA 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.